Beinaglutide 是一种重组人 GLP-1 (rhGLP-1)，与人 GLP-1(7-36) 具有几乎 100% 的同源性。Beinaglutide 在血糖控制、抑制食物摄入和胃排空和促进体重减轻方面表现出依赖于剂量的作用。Beinaglutide 具有研究超重/肥胖和非酒精性脂肪性肝炎 (NASH) 的潜力。
货号:ajcx38874
CAS:123475-27-4
分子式:C149H225N39O46
分子量：3298.61
溶解度:DMSO : 1.79 mg/mL (0.54 mM; ultrasonic and adjust pH to 5 with HCl)
纯度：98%
存储：Store at -20°C
库存：现货

Background:

Beinaglutide is a recombinant human GLP-1 (rhGLP-1) that shares almost 100% homology with human GLP-1 (7-36). Beinaglutide displays does-dependent effects in glycemic control, inhibiting food intake and gastric empty and promoting weight loss. Beinaglutide has the potential for the research of overweight/obesity and nonalcoholic steatohepatitis (NASH)[1][2].

Beinaglutide (100 nM; 48 h) increases the expression of phosphorylation of Akt in the adipocytes that were potentiated insulin-stimulated[2].

Beinaglutide (0.6, 1.2, 2.4 mg/kg; s.c.; three times per day for 7 consecutive days) shows the ability of glycemic contro, inhibits food intake and weight loss in mouse[1].Beinaglutide (150 µg/kg; s.c.; daily for 6 weeks) increases insulin sensitivity of adipocytes[2].

[1]. Fang X, et al. Beinaglutide shows significantly beneficial effects in diabetes/obesity-induced nonalcoholic steatohepatitis in ob/ob mouse model. Life Sci. 2021 Apr 1;270:118966.
[2]. Zhang F, et al. Recombinant human GLP-1 beinaglutide regulates lipid metabolism of adipose tissues in diet-induced obese mice. iScience. 2021 Oct 30;24(12):103382.